These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 29609501)

  • 1. The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis.
    Lu FB; Hu ED; Xu LM; Chen L; Wu JL; Li H; Chen DZ; Chen YP
    Expert Rev Gastroenterol Hepatol; 2018 May; 12(5):491-502. PubMed ID: 29609501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of PNPLA3 rs738409 G/C gene polymorphism with nonalcoholic fatty liver disease in children: a meta-analysis.
    Tang S; Zhang J; Mei TT; Guo HQ; Wei XH; Zhang WY; Liu YL; Liang S; Fan ZP; Ma LX; Lin W; Liu YR; Qiu LX; Yu HB
    BMC Med Genet; 2020 Aug; 21(1):163. PubMed ID: 32811452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
    Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
    Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.
    Petta S; Di Marco V; Pipitone RM; Grimaudo S; Buscemi C; Craxì A; Buscemi S
    Liver Int; 2018 Nov; 38(11):2060-2068. PubMed ID: 29577560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of non-alcoholic steatohepatitis among lean patients in Japan: Not uncommon and not always benign.
    Tobari M; Hashimoto E; Taniai M; Ikarashi Y; Kodama K; Kogiso T; Tokushige K; Takayoshi N; Hashimoto N
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1404-1410. PubMed ID: 30590868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the patatin-like phospholipase domain containing 3 gene (PNPLA3) I148M polymorphism on the risk and severity of nonalcoholic fatty liver disease and metabolic syndromes: A meta-analysis of paediatric and adolescent individuals.
    Li J; Hua W; Ji C; Rui J; Zhao Y; Xie C; Shi B; Yang X
    Pediatr Obes; 2020 Jun; 15(6):e12615. PubMed ID: 32020770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between patatin-like phospholipase domain containing 3 gene (PNPLA3) polymorphisms and nonalcoholic fatty liver disease: a HuGE review and meta-analysis.
    Xu R; Tao A; Zhang S; Deng Y; Chen G
    Sci Rep; 2015 Mar; 5():9284. PubMed ID: 25791171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.
    Chen LZ; Xin YN; Geng N; Jiang M; Zhang DD; Xuan SY
    World J Gastroenterol; 2015 Jan; 21(3):794-802. PubMed ID: 25624712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population.
    Verrijken A; Beckers S; Francque S; Hilden H; Caron S; Zegers D; Ruppert M; Hubens G; Van Marck E; Michielsen P; Staels B; Taskinen MR; Van Hul W; Van Gaal L
    Obesity (Silver Spring); 2013 Oct; 21(10):2138-45. PubMed ID: 23512881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants.
    Del Ben M; Polimeni L; Brancorsini M; Di Costanzo A; D'Erasmo L; Baratta F; Loffredo L; Pastori D; Pignatelli P; Violi F; Arca M; Angelico F
    Eur J Intern Med; 2014 Jul; 25(6):566-70. PubMed ID: 24947770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy.
    Wei JL; Leung JC; Loong TC; Wong GL; Yeung DK; Chan RS; Chan HL; Chim AM; Woo J; Chu WC; Wong VW
    Am J Gastroenterol; 2015 Sep; 110(9):1306-14; quiz 1315. PubMed ID: 26215532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PNPLA3 polymorphisms (rs738409) and non-alcoholic fatty liver disease risk and related phenotypes: a meta-analysis.
    Zhang L; You W; Zhang H; Peng R; Zhu Q; Yao A; Li X; Zhou Y; Wang X; Pu L; Wu J
    J Gastroenterol Hepatol; 2015 May; 30(5):821-9. PubMed ID: 25641744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease.
    Bugianesi E; Bizzarri C; Rosso C; Mosca A; Panera N; Veraldi S; Dotta A; Giannone G; Raponi M; Cappa M; Alisi A; Nobili V
    Am J Gastroenterol; 2017 Aug; 112(8):1277-1286. PubMed ID: 28555633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease.
    Sookoian S; Pirola CJ
    Hepatology; 2011 Jun; 53(6):1883-94. PubMed ID: 21381068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More Evidence for the Genetic Susceptibility of Mexican Population to Nonalcoholic Fatty Liver Disease through PNPLA3.
    Chinchilla-López P; Ramírez-Pérez O; Cruz-Ramón V; Canizales-Quinteros S; Domínguez-López A; Ponciano-Rodríguez G; Sánchez-Muñoz F; Méndez-Sánchez N
    Ann Hepatol; 2018 Mar; 17(2):250-255. PubMed ID: 29469042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome.
    Stättermayer AF; Traussnigg S; Aigner E; Kienbacher C; Huber-Schönauer U; Steindl-Munda P; Stadlmayr A; Wrba F; Trauner M; Datz C; Ferenci P
    J Trace Elem Med Biol; 2017 Jan; 39():100-107. PubMed ID: 27908400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NAFLD-NASH: An Under-Recognized Epidemic.
    Jennings J; Faselis C; Yao MD
    Curr Vasc Pharmacol; 2018; 16(3):209-213. PubMed ID: 28676024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH).
    Mehta R; Jeiran K; Koenig AB; Otgonsuren M; Goodman Z; Baranova A; Younossi Z
    BMC Med Genet; 2016 Sep; 17(1):63. PubMed ID: 27596100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of genetic polymorphisms in patients with nonalcoholic fatty liver disease.
    Miyaaki H; Nakao K
    Clin J Gastroenterol; 2017 Jun; 10(3):201-207. PubMed ID: 28290069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.